Categories: CancerNews

Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Webcast to be held on Monday, June 5, 2023 at 8:00 a.m. ET

WALTHAM, Mass. and BOULDER, Colo., May 23, 2023 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held Monday, June 5, 2023 at 8:00 a.m. ET (7:00 a.m. CT) to discuss lead-in data from its ongoing Phase 3 PEAK trial evaluating bezuclastinib in combination with sunitinib in patients with Gastrointestinal Stromal Tumors (GIST). The data are being presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023 at 2:15 p.m. ET (1:15 p.m. CT).

The webcast event will be led by Andrew Robbins, Cogent’s President and Chief Executive Office and will include a presentation by Andrew J. Wagner, M.D., Ph.D., Senior Physician, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School.

The live webcast can be accessed on the Investors and Media page of Cogent’s website at investors.cogentbio.com/events. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653

Staff

Recent Posts

Abridge Announces Inside for Inpatient and Initial Rollout of Outpatient Orders

SAN FRANCISCO--(BUSINESS WIRE)--Abridge, a leading generative AI platform for clinical conversations, is expanding its capabilities…

3 hours ago

Netsmart myUnity® Receives CHAP Verification for Home Health

OVERLAND PARK, Kan.--(BUSINESS WIRE)--#CHAPVerification--Netsmart, a leading provider of healthcare solutions and software for post-acute care…

3 hours ago

CharmHealth Innovation Challenge Returns With $10,000 Prize, Spotlights Agentic AI in Healthcare

Annual Competition Invites Innovators, Entrepreneurs and Developers to Shape the Future of Digital Health With…

6 hours ago

CharmHealth Innovation Challenge Returns With $10,000 Prize, Spotlights Agentic AI in Healthcare

Annual Competition Invites Innovators, Entrepreneurs and Developers to Shape the Future of Digital Health With…

6 hours ago

Backed by $2 Million, Droplet IV is Set to Launch its Revolutionary Automatic IV-Line Flushing Device in EU & US in 2026

COPENHAGEN, Denmark, June 18, 2025 /PRNewswire/ -- Droplet IV today announced the successful completion of…

6 hours ago

Dr. Renuka Kulkarni Joins Gestalt as Chief Medical Officer

SPOKANE, Wash., June 18, 2025 /PRNewswire/ -- Gestalt, a leading provider of AI-powered digital pathology…

6 hours ago